NuStar Energy (NS) Got Lower Wells Fargo Rating, 12 Analysts Covering bluebird bio (BLUE)

July 17, 2017 - By Adrian Erickson

Among 13 analysts covering Nustar Energy LP (NYSE:NS), 3 have Buy rating, 0 Sell and 10 Hold. Therefore 23% are positive. Nustar Energy LP has $64 highest and $32 lowest target. $48.44’s average target is 1.76% above currents $47.6 stock price. Nustar Energy LP had 25 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was downgraded by Stifel Nicolaus on Wednesday, November 4 to “Hold”. PiperJaffray upgraded the shares of NS in report on Tuesday, November 8 to “Overweight” rating. On Thursday, April 13 the stock rating was upgraded by Credit Suisse to “Neutral”. Stifel Nicolaus maintained the shares of NS in report on Thursday, June 29 with “Hold” rating. As per Friday, September 9, the company rating was initiated by FBR Capital. The rating was downgraded by Stifel Nicolaus on Wednesday, February 1 to “Hold”. The rating was initiated by Macquarie Research with “Neutral” on Friday, April 21. The stock of NuStar Energy L.P. (NYSE:NS) earned “Underperform” rating by Credit Suisse on Thursday, November 3. The firm earned “Buy” rating on Friday, August 12 by Citigroup. On Thursday, February 25 the stock rating was initiated by Morgan Stanley with “Equal-Weight”.

Among 19 analysts covering bluebird bio (NASDAQ:BLUE), 12 have Buy rating, 2 Sell and 5 Hold. Therefore 63% are positive. bluebird bio had 47 analyst reports since August 11, 2015 according to SRatingsIntel. Maxim Group maintained bluebird bio Inc (NASDAQ:BLUE) on Thursday, December 1 with “Buy” rating. Stifel Nicolaus initiated the shares of BLUE in report on Thursday, December 17 with “Buy” rating. Leerink Swann maintained it with “Outperform” rating and $80 target in Friday, October 14 report. The firm earned “Buy” rating on Thursday, November 5 by TH Capital. On Wednesday, February 3 the stock rating was initiated by Leerink Swann with “Outperform”. The stock of bluebird bio Inc (NASDAQ:BLUE) earned “Buy” rating by Jefferies on Friday, October 23. The rating was maintained by Morgan Stanley on Wednesday, June 14 with “Hold”. Roth Capital initiated bluebird bio Inc (NASDAQ:BLUE) on Thursday, December 3 with “Buy” rating. The company was initiated on Friday, June 3 by Cantor Fitzgerald. The rating was downgraded by Roth Capital on Monday, February 6 to “Neutral”. See bluebird bio Inc (NASDAQ:BLUE) latest ratings:

04/07/2017 Broker: Jefferies Rating: Buy New Target: $88.0000 Maintain
23/06/2017 Broker: Cowen & Co Rating: Buy Maintain
23/06/2017 Broker: Cantor Fitzgerald Rating: Sell New Target: $39.0000 Maintain
14/06/2017 Broker: Morgan Stanley Rating: Hold Maintain
07/06/2017 Broker: Janney Capital Rating: Buy New Target: $125.0000
06/06/2017 Broker: Cowen & Co Rating: Buy Maintain
06/06/2017 Broker: SunTrust Rating: Buy New Target: $108.0000
05/06/2017 Broker: Cantor Fitzgerald Rating: Sell New Target: $37.0000 Maintain
30/06/2017 Broker: BTIG Research Old Rating: Buy New Rating: Neutral Downgrade
16/06/2017 Broker: Standpoint Research Old Rating: Buy New Rating: Reduce Old Target: $110 Downgrade

The stock decreased 0.21% or $0.2 on July 14, reaching $95.8. About shares traded. bluebird bio Inc (NASDAQ:BLUE) has risen 112.34% since July 17, 2016 and is uptrending. It has outperformed by 95.64% the S&P500.

bluebird bio, Inc. is a clinical-stage biotechnology company. The company has market cap of $4.28 billion. The Firm is focused on developing gene therapies for severe diseases and cancer. It currently has negative earnings. With its lentiviral gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas.

Investors sentiment decreased to 1.29 in 2016 Q4. Its down 0.19, from 1.48 in 2016Q3. It turned negative, as 33 investors sold bluebird bio Inc shares while 51 reduced holdings. 30 funds opened positions while 78 raised stakes. 45.73 million shares or 4.13% more from 43.91 million shares in 2016Q3 were reported. Tiverton Asset Mngmt Ltd Liability owns 27,514 shares. Qvt Financial Limited Partnership holds 95,136 shares. Fmr Ltd Liability Com has invested 0.05% of its portfolio in bluebird bio Inc (NASDAQ:BLUE). 587,677 were reported by Eventide Asset Mgmt Limited Co. Alyeska Investment Group Lp stated it has 0.16% in bluebird bio Inc (NASDAQ:BLUE). State Street holds 0.01% of its portfolio in bluebird bio Inc (NASDAQ:BLUE) for 1.55M shares. Frontier Cap Mgmt Limited Co stated it has 0.1% of its portfolio in bluebird bio Inc (NASDAQ:BLUE). Deerfield Management accumulated 302,027 shares. Ubs Asset Americas owns 231,292 shares for 0.02% of their portfolio. Clearbridge Invs Limited has invested 0% in bluebird bio Inc (NASDAQ:BLUE). Cornerstone Capital Management Ltd holds 0% or 8,400 shares. First Light Asset Limited Liability Company holds 71,246 shares. Gradient Ltd Liability Company holds 0.03% in bluebird bio Inc (NASDAQ:BLUE) or 4,928 shares. Group One Trading Limited Partnership stated it has 7,941 shares. Hanseatic owns 11,650 shares for 0.4% of their portfolio.

NuStar Energy L.P. is engaged in the transportation of petroleum products and anhydrous ammonia; the terminalling and storage of petroleum products, and the marketing of petroleum products. The company has market cap of $4.52 billion. The Company’s divisions include pipeline, storage and fuels marketing. It has a 40.11 P/E ratio. The pipeline segment consists of the transportation of refined petroleum products, crude oil and anhydrous ammonia.

Analysts await NuStar Energy L.P. (NYSE:NS) to report earnings on July, 28 before the open. They expect $0.34 earnings per share, down 34.62% or $0.18 from last year’s $0.52 per share. NS’s profit will be $32.29M for 35.00 P/E if the $0.34 EPS becomes a reality. After $0.49 actual earnings per share reported by NuStar Energy L.P. for the previous quarter, Wall Street now forecasts -30.61% negative EPS growth.

Since February 2, 2017, it had 7 buys, and 0 selling transactions for $16.59 million activity. ROSIER WILLIAM GRADY also bought $9,965 worth of NuStar Energy L.P. (NYSE:NS) shares. On Wednesday, April 12 the insider GREEHEY WILLIAM E bought $15.00 million. $231,750 worth of NuStar Energy L.P. (NYSE:NS) was bought by Hill Dan J on Wednesday, April 12. $9,965 worth of NuStar Energy L.P. (NYSE:NS) shares were bought by Munch Robert J.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.